RESEARCH PROGRAM · MODELS & DOSAGE
Match the claim to the model before advancing it.
An affected person’s constitutional heterozygous ASH1L allele, an engineered heterozygous model, a complete knockout, a regional perturbation, and a rescue experiment answer different questions. This route keeps measured dosage and the bridge to human relevance explicit.
MODEL + DOSAGE DECISION FRAMEWORK
Match the claim to the model before advancing it.
An affected person’s constitutional heterozygous ASH1L allele is present across tissues, but its molecular consequence and functional dosage still must be measured. Complete, conditional, regional, and knockdown models can reveal ASH1L biology without reproducing that context. Measure the bridge; do not assume it.
Scroll horizontally to review every column.
| Model / dosage context | Measure first | Can support | Does not establish |
|---|---|---|---|
| Exact patient allele · human cells | Allele-specific RNA and protein, localization, chromatin engagement, residual function, and response to isogenic correction. | That allele’s consequence in the tested human cell state. | A shared mechanism, prognosis, or treatment response. |
| Engineered heterozygous loss model | Actual RNA, protein, and functional output across a measured dosage series. | A controlled heterozygous-loss question in a defined cell state and time. | Equivalence to a patient allele without a direct molecular match. |
| Complete or homozygous loss | Residual ASH1L output, viability, cell composition, and perturbation effect. | Dependency mapping and mechanism discovery. | Heterozygous human dosage, severity, or response. |
| Conditional, regional, or knockdown loss | Perturbation site, timing, method, and measured molecular or functional reduction. | Cell-, region-, or time-specific necessity. | Germline, whole-body patient-allele relevance. |
| Correction or rescue | Predefined readouts, dose, timing, durability, toxicity, and replication. | Causality or modifiability within that model. | A safe or effective human treatment. |
Dosage means measured molecular or functional output in the stated assay and model. A genotype, construct, or model label does not supply a percentage.
GO
Advance the specific claim.
Proceed when the primary molecular consequence is measured, the effect reproduces across appropriate controls, and correction or rescue moves the predefined result as expected. Human relevance additionally requires testing the exact patient allele in a measured heterozygous context.
HOLD
Keep the claim provisional.
Hold when dosage is inferred; only one allele, model, cell state, assay, or laboratory supports the result; alternatives remain; or patient-allele and heterozygous human relevance have not been tested. Name the next decisive comparison.
STOP
Stop that proposed link.
Stop when the effect fails independent replication, disappears after viability, maturation, composition, clone, or batch controls, does not attenuate under validated correction or rescue, or depends on unacceptable toxicity. Do not translate a model rescue directly into a human treatment claim.
Decision boundary: Go, hold, and stop apply to the proposed claim or model chain—not to the established ASH1L gene–disease relationship. A stopped link narrows the program.
TRANSLATIONAL EVIDENCE PATH
Every arrow is a separate claim.
Functional ASH1L output, cell-state effects, response kinetics, human patterns, and treatment relevance must each be measured.
DISCOVERY → TRANSLATION
5 stages, each requiring stronger evidence.
If one step is not supported, that proposed link must be revised or set aside. It does not undo the established ASH1L gene–disease relationship.
- 01 · COMMUNITY INFORMATION
Discover
Generate hypotheses from structured molecular, clinical, and longitudinal observations without treating the connected group as a population cohort.
- 02 · INDEPENDENT SAMPLE
Confirm
Reproduce the observation prospectively with fixed definitions, complete denominators, adequate controls, and pre-specified analysis.
- 03 · TEMPORAL MODEL
Explain
Show temporal order, compare plausible mediators, and test whether correction or rescue changes the proposed link.
- 04 · EXTERNAL VALIDITY
Generalize
Replicate across alleles, cell states, ages, sexes, laboratories, and an independent human cohort where the question requires it.
- 05 · CLINICAL UTILITY
Translate
Advance only after safety, target engagement, meaningful outcomes, feasibility, ethical oversight, and regulatory requirements are met.
DETAILED STUDY DESIGN · PDF
Open the full challenge-and-recovery study design.
For this research question: reduced reserve means a measurable difference in threshold, response coordination, shutoff, recovery, or re-challenge after baseline adjustment. It is not a diagnosis, severity label, or proof of one shared human mechanism.
The research brief describes 4 controlled dimensions, 6 ordered timepoints, required molecular and functional measurements, criteria for rescue and replication, results that would challenge the hypothesis, safety limits, and the populations to be analyzed.
Limit: this is a proposed preclinical study design; it does not guide treatment.